Free tool
FAERS Monitor: Aczone
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 207154 or its brand name (Aczone, Dapsone). Reports on generic versions are filed under their own applications.
Reports
10,863
Serious
8,218
76% of reports
Hospitalization
3,865
Death reported
935
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- off label use1,306
- drug ineffective1,166
- methaemoglobinaemia498
- nausea492
- fatigue487
- pyrexia474
- diarrhoea426
- rash405
- drug reaction with eosinophilia and systemic symptoms399
- dyspnoea392
- pneumonia385
- pain376
- anaemia374
- condition aggravated366
- treatment failure364
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 143 |
| 2005 | 145 |
| 2006 | 165 |
| 2007 | 104 |
| 2008 | 193 |
| 2009 | 232 |
| 2010 | 212 |
| 2011 | 232 |
| 2012 | 274 |
| 2013 | 173 |
| 2014 | 311 |
| 2015 | 441 |
| 2016 | 566 |
| 2017 | 647 |
| 2018 | 732 |
| 2019 | 733 |
| 2020 | 927 |
| 2021 | 709 |
| 2022 | 807 |
| 2023 | 687 |
| 2024 | 872 |
| 2025 | 890 |
| 2026 | 665 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,043,296 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| methaemoglobinaemiaSignal | 498 | 530.3 | 481.2 | 206,172 |
| drug reaction with eosinophilia and systemic symptomsSignal | 399 | 30.5 | 27.7 | 11,185 |
| treatment failureSignal | 364 | 8.5 | 7.7 | 2,415 |
| anaemiaSignal | 374 | 3.8 | 3.4 | 775 |
| off label useSignal | 1,306 | 2.9 | 2.7 | 1,681 |
| pyrexiaSignal | 474 | 2.7 | 2.4 | 495 |
| condition aggravatedSignal | 366 | 2.3 | 2.1 | 281 |
| pneumoniaSignal | 385 | 2.3 | 2.1 | 287 |
| rash | 405 | 1.8 | 1.6 | 146 |
| drug ineffective | 1,166 | 1.7 | 1.6 | 369 |
| dyspnoea | 392 | 1.3 | 1.2 | 35 |
| diarrhoea | 426 | 1.3 | 1.2 | 26 |
| fatigue | 487 | 1.2 | 1.1 | 18 |
| nausea | 492 | 1.2 | 1.1 | 17 |
| pain | 376 | 1.2 | 1.1 | 11 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.